Total Funding
2
Total FundingPrivate Equity raised
Growth Score in past quarter
pts
Heat Score 2 in past quarter
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
920222
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
Acquired by 
Emergent BioSolutions
Kenneth Kelley: Co-Founder, CEO & DirectorPast Role: IntraBiotics Pharmaceuticals, Founder/CEO and Chairman
Past Role: Acambis, Chief Scientific Officer and Executive Director
About the Company
PaxVax is a vaccine start-up company developing candidate oral vaccines for influenza, and key infectious diseases. It has developed a proprietary oral vaccine technology based on a common virus called adenovirus. The technology removes the delivery hurdles of traditional injectable vaccines, namely the need for cold storage, needles, and
administration by medical personnel.
PaxVax was founded in 2007 and is headquartered in Gaithersburg, Maryland.


